Sector Update: Healthcare

By Staff,

Shutterstock photo

Healthcare shares were generally flat in pre-market trade Thursday.

In healthcare stocks news, Regado BioSciences ( RGDO ) has announced the Data Safety Monitoring Board has initiated an unplanned review of data from the REGULATE-PCI trial, a Phase 3 trial.

The trial enrolled 13,200 patients with acute coronary syndromes undergoing percutaneous coronary intervention. Patient enrollment has been paused until the DSMB has completed its analysis and communicated its recommendations, anticipated within the next eight weeks.

Shares of RGDO are down in early pre-market trading with a 52-week range of $4.27 - $14.10.

And, PTC Therapeutics, Inc. ( PTCT ) initiated a global confirmatory Phase 3 clinical trial of Translarna, an investigational new drug, in patients with nonsense mutation cystic fibrosis.

Nonsense mutations within cystic fibrosis are categorized as Class I mutations, a severe form of CF that results in little or no production of the CFTR protein.

Finally, Tekmira Pharmaceuticals (TKMR, TKM.TO) said it has been advised by the U.S. FDA that the TKM-Ebola Phase I healthy volunteer clinical study has been placed on clinical hold.

The dual-listed biopharmaceutical company said the study has been put on hold, pending additional data related to the mechanism of cytokine release, observed at higher doses, to ensure the safety of healthy volunteer subjects.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2014 All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing Commodities
Referenced Stocks: RGDO , PTCT

More from MT Newswires


MT Newswires

MT Newswires

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by